Car T-Cell Therapy

Tisagenlecleucel may be less toxic than axicabtagene ciloleucel for patients with relapsed or refractory follicular lymphoma, study results suggested.

Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line therapy than standard treatment for relapsed or refractory large B-cell lymphoma, according to study results.

The FDA granted regenerative medicine advanced therapy designation to obecabatagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

The addition of utomilumab after infusion with axicabtagene ciloleucel induced a 75% response rate among adults with relapsed or refractory large B-cell lymphoma, data from the ZUMA-11 trial showed.

Fludarabine exposure appeared associated with improved clinical outcomes among pediatric patients undergoing chimeric antigen receptor T-cell therapy for refractory or relapsed B-cell acute lymphoblastic leukemia, study results showed.

The FDA granted orphan drug designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.

A bispecific chimeric antigen receptor T-cell therapy continues to show promising efficacy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, results of a phase 1/phase 2 trial suggest.

SALT LAKE CITY — Ciltacabtagene autoleucel induced a 95% overall response rate among patients with multiple myeloma who had early relapse after front-line therapy, according to results of a cohort analysis from the CARTITUDE-2 trial.

Younger patients with diffuse midline glioma experienced prolonged clinical improvement after receiving an investigational chimeric antigen receptor T-cell therapy, study results demonstrated.